trending Market Intelligence /marketintelligence/en/news-insights/trending/MKU6FOBebd_813xhv0xCrg2 content esgSubNav
In This List

Relmada Therapeutics raises $115M from stock offering

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Relmada Therapeutics raises $115M from stock offering

Relmada Therapeutics Inc. raised $115 million from a public offering of shares after underwriters exercised an option to buy additional stock.

The New York-based pharmaceutical company offered 3,833,334 shares at $30 apiece, including 500,000 shares as part of underwriters' overallotment option.

Relmada intends to use the gross proceeds from the offering to fund the research and development of its treatment-resistant depression drug REL-1017, or dextromethadone, and for general corporate purposes.

Jefferies, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.